A Bioanalytical Method for Eliglustat Quantification in Rat Plasma

Reddy, Venkata Krishna; Swamy, Narayana; Rathod, Rajeswari; Sengupta, Pinaki

doi:10.1093/chromsci/bmz033

Cited by 13 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we developed and established a UPLC-MS/MS method for the determination of eliglustat in rat plasma. To the best of our knowledge, only one paper had described a bioanalytical method of determining eliglustat in plasma by HPLC prior, which required elaborate sample preparation (liquid–liquid extraction), low sensitivity (300 ng/mL), and long run time (12 minutes) 18. We instead chose a simple protein-precipitation method using acetonitrile.…”

Section: Discussionmentioning

confidence: 99%

<p>Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats</p>

Wang¹,

Wang²,

Zhong³

et al. 2019

DDDT

View full text Add to dashboard Cite

BackgroundEliglustat, a new oral substrate-reduction therapy, was recently approved as a first-line therapy for Gaucher's disease type 1 (GD1) patients.PurposeThe purpose of the present study was to develop and validate a simple UPLC-MS/MS method for the measurement of plasma-eliglustat concentration and to investigate the effects of amiodarone and quinidine on eliglustat metabolism in rats.MethodsEighteen rats were randomly divided into three groups (n=6): control (0.5% CMC-Na, group A), amiodarone (60 mg/kg, group B), and quinidine (100 mg/kg, group C). Thirty minutes later, 10 mg/kg eliglustat was orally administered to each rat and concentrations of eliglustat in the rats determined by our UPLC-MS/MS method.ResultsAmiodarone and quinidine increased the main pharmacokinetic parameters (AUC0→t, AUC0→∞, and Cmax) of eliglustat significantly and decreased clearance obviously.ConclusionAmiodarone and quinidine can elevate eliglustat exposure and have an inhibitory effect on eliglustat metabolism. Clearly, appropriate pharmacological studies of eliglustat in patients treated with amiodarone or quinidine should be done in future.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats</p>

Wang¹,

Wang²,

Zhong³

et al. 2019

DDDT

View full text Add to dashboard Cite

show abstract

“…Three chemical structures of ELGS stereoisomers, namely, (1R,2S)-stereoisomer, (1S,2R)-stereoisomer, and (1S,2S)stereoisomer, are represented in Figure 1. [3,4] From the review of literature, there are only two highperformance liquid chromatography (HPLC) methods [5,6] that have been reported for the estimation of ELGS and no chiral HPLC method iswas reported for the quantitation of ELGS and its stereoisomers. In the present research paper, chromatographic method was developed with immobilized Amylose tris (3-chloro-4-methylphenylcarbamate) chiral stationary phase namely CHIRALPAK IF-3(4.6 mm × 250 mm, 3 µm), utilized for the separation and quantification of ELGS isomers.…”

Section: Introductionmentioning

confidence: 99%

Untitled

Srinivasu¹

2021

AJP

View full text Add to dashboard Cite

Aim:The main aim of the present work is to develop and validate a new simpler, selective, specific, and robust high performance liquid chromatographic method for the separation of Eliglustat and its isomers. Materials and Methods: For the accurate quantification method, for the all isomers was developed by performing the significant number of methods on trial and error techniques using a large number of polar and non-polar solvent mixtures as mobile phase. A distinctive resolution between Eliglustat and its stereo isomers was achieved on Immobilized Amylose tris (3-chloro-4-methylphenylcarbamate) stationary phase namely CHIRALPAK IF-3(4.6 mm × 250 mm, 3 µm), with flow rate of 1.0 mL/min using isocratic method containing n-

show abstract

“…The symptoms and progression of RA can be controlled by treatment strategies, which include non-steroidal anti-inflammatory drugs (relives from pain and stiffness), corticosteroids (minimize the inflammatory events) and DiseaseModifying Antirheumatic Drugs (DMARDs) (suppress progression of RA). 24 However, rheumatologists preferred to prescribe combination therapy rather than monotherapy because of the increased efficacy and enhanced improvement of the patient over time. 5 Dell et al performed a two years study and measured the difference in the improvement of patients with three different treatments i.e, Methotrexate (MXT) alone, Sulfasalazine (SFS) and Hydroxychloroquine (HCQ) combined treatment and combination of all three.…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Simultaneous Bioanalytical Method for Methotrexate, Sulfasalazine and Hydroxychloroquine in Rat Plasma following Single Step Protein Precipitation Technique

Reddy¹,

Sahu²,

Sharma³

et al. 2020

IJPER

Self Cite

View full text Add to dashboard Cite

Background: Triple therapy of methotrexate, sulfasalazine and hydroxychloroquine is widely used in the treatment of rheumatoid arthritis. Different studies reported the superior efficacy of combination of these three drugs in the improvement of this disease state. However, there is still a lot of scopes remains for preclinical study of this combination in future. Establishment of bioanalytical method is essential for quantitating these analytes in the samples from such types of studies. Therefore, in this study, we aim to develop a simultaneous method for quantification of methotrexate, sulfasalazine and hydroxychloroquine in rat plasma through a single run. Materials and Methods: The method includes a simple single step protein precipitation technique for extraction of all the three analytes from rat plasma with more than 84% recovery. The method was validated according to the USFDA guideline for a calibration range of 0.50-10μg/mL. Results: Overall, the method showed acceptable accuracy (92.14-116.12%) and precision (%coefficient of variation; 0.79-11.94%) at lower limit of quantification and three quality control levels. Analytes were found to be stable in all the tested stability study conditions. Conclusion: We have established a simultaneous bioanalytical method for methotrexate, sulfasalazine and hydroxychloroquine in rat plasma. Applicability of the method has been established through an oral pharmacokinetic study of the combination in rat.

show abstract

A Bioanalytical Method for Eliglustat Quantification in Rat Plasma

Cited by 13 publications

References 15 publications

<p>Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats</p>

<p>Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats</p>

Untitled

Development and Validation of a Simultaneous Bioanalytical Method for Methotrexate, Sulfasalazine and Hydroxychloroquine in Rat Plasma following Single Step Protein Precipitation Technique

Contact Info

Product

Resources

About